Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof

Abstract

Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.

1 . A synthetic pediatric formula comprising a human milk oligosaccharide and from about 0.025 mM to about 1 mM of a long chain polyunsaturated fatty acid. 
     
     
         2 . The synthetic pediatric formula of  claim 1 , wherein the human milk oligosaccharide is selected from the group consisting of 6′-sialyllactose, 3′-sialyllactose, 2′-fucosyllactose, 3-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose, lacto-N-fucopentaose, and combinations thereof. 
     
     
         3 . The synthetic pediatric formula of  claim 1 , wherein the human milk oligosaccharide is present in an amount of from about 0.001 mg/mL to about 20 mg/mL and is selected from the group consisting of 6′-sialyllactose, 3′-sialyllactose, 2′-fucosyllactose, lacto-N-neotetraose, and combinations thereof. 
     
     
         4 . The synthetic pediatric formula of  claim 1 , wherein the long chain polyunsaturated fatty acid is selected from the group consisting of linoleic acid, linolenic acid, arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid, and combinations thereof. 
     
     
         5 . The synthetic pediatric formula of  claim 1 , wherein the long chain polyunsaturated fatty acid is arachidonic acid, docosahexaenoic acid, or a combination of both. 
     
     
         6 . The synthetic pediatric formula of  claim 1 , wherein the human milk oligosaccharide is 6′-sialyllactose. 
     
     
         7 . The synthetic pediatric formula of  claim 6 , wherein the 6′-sialyllactose is present in a concentration of from about 0.001 mg/mL to about 20 mg/mL. 
     
     
         8 . The synthetic pediatric formula of  claim 1 , wherein the human milk oligosaccharide is 2′-fucosyllactose. 
     
     
         9 . The synthetic pediatric formula of  claim 8 , wherein the 2′-fucosyllactose is present in a concentration of from about 0.001 mg/mL to about 1 mg/mL. 
     
     
         10 . The synthetic pediatric formula of  claim 1 , further comprising from about 0.001 μg/mL to about 10 μg/mL of a carotenoid. 
     
     
         11 . The synthetic pediatric formula of  claim 10 , wherein the carotenoid is present in a concentration of from about 0.001 μg/mL to about 5 μg/mL. 
     
     
         12 . The synthetic pediatric formula of  claim 10 , wherein the carotenoid is selected from the group consisting of lutein, lycopene, beta-carotene, and combinations thereof. 
     
     
         13 . The synthetic pediatric formula of  claim 1  further comprising from about 10 mg/L to about 200 mg/L of a nucleotide. 
     
     
         14 . The synthetic formula of  claim 13 , wherein the nucleotide is present in an amount of from about 42 mg/L to about 102 mg/L. 
     
     
         15 . A synthetic formula selected from a synthetic pediatric formula and a synthetic child formula, the synthetic formula comprising a human milk oligosaccharide selected from the group consisting of 6′-sialyllactose, 3′-sialyllactose, 2′-fucosyllactose, 3-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose, lacto-N-fucopentaose, and combinations thereof, from about 0.025 mM to about 1 mM of a long chain polyunsaturated fatty acid, and from about 0.001 μg/mL to about 10 μg/mL of a carotenoid. 
     
     
         16 . The synthetic formula of  claim 15 , wherein the human milk oligosaccharide is selected from the group consisting of 6′-sialyllactose, 3′-sialyllactose, 2′-fucosyllactose, lacto-N-neotetraose, and combinations thereof. 
     
     
         17 . The synthetic formula of  claim 15 , wherein the long chain polyunsaturated fatty acid is selected from the group consisting of linoleic acid, linolenic acid, arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid, and combinations thereof. 
     
     
         18 . The synthetic formula of  claim 15 , wherein the long chain polyunsaturated fatty acid is arachidonic acid, docosahexaenoic acid, or a combination of both. 
     
     
         19 . The synthetic formula of  claim 15 , wherein the carotenoid is present in a concentration of from about 0.001 μg/mL to about 5 μg/mL. 
     
     
         20 . The synthetic formula of  claim 15 , wherein the carotenoid is selected from the group consisting of lutein, lycopene, beta-carotene, and combinations thereof. 
     
     
         21 . The synthetic formula of  claim 15 , wherein the human milk oligosaccharide is present in an amount of about 0.1 mg/mL to about 2 mg/mL. 
     
     
         22 . A method of reducing inflammation in an infant, toddler, or child in need thereof, the method comprising administering to the infant, child or toddler a synthetic formula selected from a synthetic pediatric formula and a synthetic child formula, the synthetic formula comprising a human milk oligosaccharide, from about 0.025 mM to about 1 mM of a long chain polyunsaturated fatty acid, and from about 0.001 μg/mL to about 10 μg/mL of a carotenoid. 
     
     
         23 . The method of  claim 22 , wherein the human milk oligosaccharide is selected from the group consisting of 6′-sialyllactose, 3′-sialyllactose, 2′-fucosyllactose, 3-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose, lacto-N-fucopentaose, and combinations thereof. 
     
     
         24 . The method of  claim 22 , wherein the human milk oligosaccharide is selected from the group consisting of 6′-sialyllactose, 3′-sialyllactose, 2′-fucosyllactose, lacto-N-neotetraose, and combinations thereof. 
     
     
         25 . The method of  claim 22 , wherein the long chain polyunsaturated fatty acid is selected from the group consisting of linoleic acid, linolenic acid, arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid, and combinations thereof. 
     
     
         26 . The method of  claim 25 , wherein the long chain polyunsaturated fatty acid is arachidonic acid, docosahexaenoic acid, or a combination of both. 
     
     
         27 . The method of  claim 22 , wherein the carotenoid is present in a concentration of from about 0.001 μg/mL to about 5 μg/m L. 
     
     
         28 . The method of  claim 28 , wherein the carotenoid is selected from the group consisting of lutein, lycopene, beta-carotene, and combinations thereof. 
     
     
         29 . The method of  claim 22 , wherein the synthetic formula further comprises from about 10 mg/L to about 200 mg/L of a nucleotide. 
     
     
         30 . The method of  claim 29 , wherein the nucleotide is present in an amount of from about 42 mg/L to about 102 mg/L.